Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Redasemtide Yields Positive PII Data in Stroke: Shionogi/StemRIM
December 14, 2021
- Tenapanor Hits Mark in Japan Hyperphosphatemia Study: Kyowa Kirin
December 14, 2021
- Daiichi Sankyo’s Valemetostat Logs 48% Response in Japan ATL Study
December 14, 2021
- Takeda Spinout ARTham Now a Kaken Subsidiary
December 14, 2021
- Lilly’s RET Inhibitor, Pfizer’s Oral JAK Drug Make Japan Debut
December 14, 2021
- Chugai Files Actemra for COVID-19 Pneumonia in Japan
December 14, 2021
- J-TEC’s Ocural, Cell Sheet for Eye Disease, Launched in Japan
December 13, 2021
- Mitsubishi Tanabe Eyes US Submission of Oral Edaravone by March-End
December 13, 2021
- Teva Takeda to Roll Out 2nd Blopress AG in January
December 13, 2021
- Novo’s Sogroya Now Available in Japan, Listing Came 10 Months after Approval
December 13, 2021
- Chugai’s Polivy Filed for First-Line DLBCL Treatment in Japan
December 13, 2021
- Takeda Seeks Pediatric Nod for HAE Drug Firazyr in Japan
December 13, 2021
- 7 Companies Launch E Keppra Generics upon Listing
December 13, 2021
- Authorized Generics for Edirol, Vesicare, Vegamox, and More in December Listing
December 10, 2021
- 1st Lucentis Biosimilar Launched in Japan, Senju Eyes 6.9 Billion Yen in 5th Year
December 10, 2021
- Latuda’s Use Patent Dismissed in US; Dainippon Sumitomo Plans to Appeal
December 10, 2021
- Daiichi Sankyo to Speed Up TROP2-Directed ADC Program for Breast Cancer
December 9, 2021
- Opdivo Nabs Top Slot in Japan Sales Ranking in November: Encise
December 9, 2021
- Roche/Chugai’s Tocilizumab Approved for Severe COVID-19 in Europe
December 8, 2021
- Santen Bags Global Rights to Aerie’s Glaucoma Meds, Except US, in Expanded Pact
December 8, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…